Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | CCR3 | P51677 | 2/20 | 0.62 |
| ▸ | MC4R | P32245 | 5/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9366741 | 0.84 | CYP1A2 (0.96) | CYP2D6CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL16226720 | 0.83 | SLC6A4 (0.68) | CYP2D6CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL3715253 | 0.82 | CYP1A2 (1.00) | CYP2D6CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL14593276 | 0.82 | MC4R (0.69) | CYP2D6TSHRCYP2C19SLC6A4SLC6A2 | |
| SCHEMBL14731798 | 0.81 | CYP1A2 (0.68) | CYP2D6CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL11504609 | 0.81 | CYP1A2 (0.68) | CYP2D6CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL14722649 | 0.81 | CYP1A2 (0.68) | CYP2D6CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL11504581 | 0.81 | CYP1A2 (0.62) | CYP2D6CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL25375773 | 0.81 | MC4R (0.62) | CYP2D6TSHRCYP2C19SLC6A4SLC6A2 | |
| SCHEMBL2843665 | 0.81 | MC4R (0.62) | CYP2D6TSHRCYP2C19SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0346791-A1 | 1,2-diarylethylamines for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1989-12-20 | — | — | EP | claimed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| EP-0346791-B1 | 1,2-diarylethylamines for treatment of neurotoxic injury | SEARLE & CO (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0346791-A1 | 1,2-diarylethylamines for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | CYP2D6 1097/4885CYP1A2 998/4885CYP3A4 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.